Figure 6
Combination treatment of dasatinib and irinotecan showed synergistic antitumour efficacy in HepG-2 xenografts.Nude mice transplanted with HepG-2 xenografts were treated with dasatinib (100 mg kg−1, i.g.), irinotecan (1 mg kg−1, i.p.), combination or vehicle for 30 days(n=6 per group). (A) Morphology of tumours are shown and the weight of tumour were described as the mean±s.e.m. *Compared with the monotherapy groups, P<0.05. (B) Tumour volume and relative tumour volume are shown and described as the mean±s.e.m., and their corresponding tumour inhibition rates at day 30 are also shown in the table. *Compared with the monotherapy groups, P<0.05. (C) Average body weights are shown and expressed as the mean±s.e.m. (D) Western blotting showed cleaved PARP, cleaved caspase-3, PLK1 and GAPDH from proteins extracted from tumour tissues of different groups of mice.
